Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company specializing in biomarker and augmented intelligence solutions for chronic low back pain, announced a commercial agreement with Weill Cornell Medicine to deploy its Nociscan platform in a groundbreaking clinical trial. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center, where a multidisciplinary spine team led by Dr. Jaspal Ricky Singh will integrate the technology into a study of bone marrow aspirate stem cell concentrate (BMAC) for osteoarthritis and degenerative disc disease.
The trial, titled "A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease" (IRB Protocol No. 22-06024915), aims to investigate whether the dose and quantity of BMAC affect patient-reported functional outcomes and pain. A subset of patients selected by Dr. Singh will undergo Nociscan scanning to identify painful discs. Dr. Singh, Vice Chair and Director of Interventional Spine at Weill Cornell Medicine, emphasized the comprehensive approach: “Our team takes a comprehensive approach to the treatment of spinal disorders... Our pioneering research into discogenic low back pain and cBMA is an ideal opportunity to utilize the insights provided by Nociscan.”
Chronic low back pain (cLBP) affects approximately 266 million people worldwide, driving demand for precise diagnostic tools. Aclarion’s Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful lumbar discs by quantifying chemical biomarkers associated with disc pain via magnetic resonance spectroscopy (MRS). When combined with other diagnostic methods, Nociscan provides critical insights into pain location, and studies show improved outcomes when all Nociscan-positive discs are treated.
This collaboration marks a significant expansion of Nociscan’s clinical utility, moving beyond standalone diagnostics into regenerative medicine trials. If successful, the study could validate Nociscan as a tool to guide stem cell therapy, potentially personalizing treatment for discogenic pain. The agreement also strengthens Aclarion’s presence in academic medicine, as Weill Cornell is a leading research institution. For more information about Aclarion and Nociscan, visit www.aclarion.com or view the company’s latest news at https://tinyurl.com/aconnewsroom.
